Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update

被引:10
作者
Zanetti, Hugo Ribeiro [1 ,2 ]
Roever, Leonardo [2 ]
Goncalves, Alexandre [1 ,2 ,3 ,4 ]
Resende, Elmiro Santos [2 ]
机构
[1] Master Inst Educ President Antonio Carlos, Ave Minas Gerais,1889 Ctr, BR-38440046 Araguari, MG, Brazil
[2] Univ Fed Uberlandia, Dept Clin Res, Uberlandia, MG, Brazil
[3] Univ Paulista, Brasilia, DF, Brazil
[4] Atenas Coll, Paracatu, MG, Brazil
关键词
HIV; Antiretroviral therapy; HMG-CoA reductase inhibitor; Cardiovascular disease; COA REDUCTASE INHIBITORS; CARDIOVASCULAR-DISEASE; HEART-FAILURE; HIV-INFECTION; RISK; ROSUVASTATIN; CORONARY; SAFETY; ATORVASTATIN; PRAVASTATIN;
D O I
10.1007/s11883-018-0708-z
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Purpose of Review This clinical update is intended to focus in relationship between HIV infection and use of antiretroviral therapy (ART) and statin. Recent Findings Though ART significantly changed the course of HIV infection, it is related to numerous side effects principally to the lipid profile. In this way, statins became one of the most used lipid-lowering therapies in this population. In our clinical update, we evaluated studies that demonstrate the relationship and molecular mechanisms that HIV infection and ART use trigger dyslipidemia and also the use of statin to reduce this condition. Summary We have demonstrated that use of statin can be used in dyslipidemic HIV-infected people as long as there is no drug interaction with ART. Recently, studies using rosuvastatin have shown greater effects when compared to the other statins.
引用
收藏
页数:6
相关论文
共 60 条
  • [1] Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial
    Aslangul, Elisabeth
    Assoumou, Jambert
    Bittar, Randa
    Valantin, Marc-Antoine
    Kalmykova, Olga
    Peytavin, Gilles
    Fievet, Marie-Helene
    Boccara, Franck
    Bonnefont-Rousselot, Dominique
    Melchior, Jean-Claude
    Giral, Philippe
    Costagliola, Dominique
    [J]. AIDS, 2010, 24 (01) : 77 - 83
  • [2] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    Baigent, C
    Keech, A
    Kearney, PM
    Blackwell, L
    Buck, G
    Pollicino, C
    Kirby, A
    Sourjina, T
    Peto, R
    Collins, R
    Simes, J
    [J]. LANCET, 2005, 366 (9493) : 1267 - 1278
  • [3] Falcao MDBD, 2012, ARQ BRAS CARDIOL, V99, P971
  • [4] Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study
    Bruckert, E
    Hayem, G
    Dejager, S
    Yau, C
    Bégaud, B
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (06) : 403 - 414
  • [5] Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients
    Calza, L
    Manfredi, R
    Chiodo, F
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (01) : 10 - 14
  • [6] Rosuvastatin, Pravastatin, and Atorvastatin for the Treatment of Hypercholesterolaemia in HIV-Infected Patients Receiving Protease Inhibitors
    Calza, Leonardo
    Manfredi, Roberto
    Colangeli, Vincenzo
    Pocaterra, Daria
    Pavoni, Michele
    Chiodo, Francesco
    [J]. CURRENT HIV RESEARCH, 2008, 6 (06) : 572 - 578
  • [7] Statin Therapy Decreases Serum Levels of High-Sensitivity C-Reactive Protein and Tumor Necrosis Factor-α in HIV-Infected Patients Treated With Ritonavir-Boosted Protease Inhibitors
    Calza, Leonardo
    Trapani, Filippo
    Bartoletti, Michele
    Manfredi, Roberto
    Colangeli, Vincenzo
    Borderi, Marco
    Grossi, Gabriele
    Motta, Roberto
    Viale, Pierluigi
    [J]. HIV CLINICAL TRIALS, 2012, 13 (03): : 153 - 161
  • [8] Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    Cannon, CP
    Braunwald, E
    McCabe, CH
    Rader, DJ
    Rouleau, JL
    Belder, R
    Joyal, SV
    Hill, KA
    Pfeffer, MA
    Skene, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) : 1495 - 1504
  • [9] Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
    Carr, A
    Samaras, K
    Chisholm, DJ
    Cooper, DA
    [J]. LANCET, 1998, 351 (9119) : 1881 - 1883
  • [10] Drug interactions with statins
    Causevic-Ramosevac, Anida
    Semiz, Sabina
    [J]. ACTA PHARMACEUTICA, 2013, 63 (03) : 277 - 293